公开(公告)号：EP1446498B1

公开(公告)日：2008-03-12

申请号：EP02790358.2

申请日：2002-11-08

申请人： Tibotec Pharmaceuticals Ltd. ,  Aaron Diamond Aids Research Center ,  THE ROCKEFELLER UNIVERSITY

发明人： GULNIK, Sergei ,  YU, Betty ,  ERICKSON, John, W. ,  MARKOWITZ, Martin c/o Aaron Diamond Aids Res.Cent.

IPC分类号： C12Q1/37

CPC分类号： C12Q1/37 ,  C12Q1/703 ,  G01N2333/161

公开(公告)号：EP1855112A1

公开(公告)日：2007-11-14

申请号：EP06300450

申请日：2006-05-10

申请人： INST NAT SANTE RECH MED

发明人： BERLIOZ-TORRENT CLARISSE ,  BENAROUS RICHARD ,  LOPEZ-VERGES SANDRA

IPC分类号： G01N33/68 ,  C07K14/16 ,  G01N33/569

CPC分类号： C07K14/005 ,  A61K38/00 ,  C12N2740/16222 ,  G01N33/56988 ,  G01N2333/161 ,  G01N2500/02

摘要： Method for the in vitro screening of compounds that inhibit Env glycoprotein incorporation into HIV-1 virions in cells infected by a HIV-1 virus, wherein said method comprises the following steps a) determining the ability of a candidate compound to inhibit the interaction between (i) the HIV-1 Gag protein and (ii) the TIP47 protein; and b) selecting positively the candidate compound(s) that inhibit the interaction between (i) the HIV-1 Gag protein and (ii) the TIP47 protein.

摘要翻译： 用于化合物的体外筛选方法确实抑制Env糖蛋白掺入到HIV-1病毒粒子以由HIV-1病毒感染细胞，worin所述方法包括以下步骤：a）确定的采矿的候选化合物的能力来抑制之间的相互作用（ i）所述HIV-1 Gag蛋白和（ii）所述蛋白质TIP47; 和b）选择正候选化合物（S）并抑制（i）所述HIV-1 Gag蛋白和（ii）所述蛋白质TIP47之间的相互作用。

公开(公告)号：EP1242818B1

公开(公告)日：2004-04-21

申请号：EP00987612.9

申请日：2000-12-14

申请人： BioStrands S.r.l.

发明人： MENZO, Stefano, Uni. Ancona, Ist. de Microbiologia ,  CLEMENTI, Massimo

IPC分类号： G01N33/50 ,  G01N33/569 ,  C12Q1/70 ,  C12N9/50

CPC分类号： G01N33/5091 ,  G01N33/5008 ,  G01N33/502 ,  G01N2333/161

摘要： A method to evaluate the sensitivity of an HIV variant from a biological sample to at least one drug able to inhibit the HIV protease is disclosed. The method comprises the steps of: a) amplifying the nucleic acid encoding the HIV protease from the biological sample, to obtain an amplified HIV protease coding sequence; b) cloning the amplified HIV protease coding sequence into a unique restriction site of a modified HIV molecular clone, wherein said modified HIV molecular clone is modified at least by deleting the protease coding sequence and by replacing it with the unique restriction site, to obtain a recombinant HIV molecular clone comprising and expressing the HIV protease coding sequence; c) introducing the recombinant HIV molecular clone comprising and expressing the HIV protease coding sequence into cultured cells, to obtain recombinant HIV transfected cells; d) measuring the level of HIV p24 antigen into the cell supernatant of the recombinant HIV transfected cells both in the presence and in the absence of the drug able to inhibit the HIV protease. The method is suitable for any HIV variant, both HIV-1 or HIV-2 variants. Diagnostic kits are also disclosed.

公开(公告)号：EP1110089A1

公开(公告)日：2001-06-27

申请号：EP99945158.6

申请日：1999-08-23

申请人： Abbott Laboratories

发明人： SHAH, Dinesh, O. ,  WACKOWIAK, James, P. ,  DUBOVOY, Natalie

IPC分类号： G01N33/58

CPC分类号： G01N33/582 ,  G01N2333/15 ,  G01N2333/161 ,  G01N2333/162 ,  G01N2333/44 ,  Y10S435/968 ,  Y10S435/969 ,  Y10S435/971 ,  Y10S435/974 ,  Y10S435/975

摘要： The invention relates generally to immunoassays for detection of antibodies by use of chemiluminescent compounds. More particularly, the invention relates to chemiluminescent immunoassays to detect antibodies wherein a precomplex mixture is created and a two-step assay is performed resulting in a greater signal.

公开(公告)号：EP2776463A4

公开(公告)日：2015-03-25

申请号：EP12847241

申请日：2012-11-07

申请人： US HEALTH

发明人： CONNORS MARK ,  HUANG JINGHE ,  LAUB LEO B ,  KWONG PETER ,  NABEL GARY ,  MASCOLA JOHN R ,  ZHANG BAOSHAN ,  RUDICELL REBECCA S ,  GEORGIEV IVELIN ,  YANG YONGPING ,  ZHU JIANG ,  OFEK GILAD

IPC分类号： C07K16/10 ,  A61K39/42 ,  A61P31/18 ,  C12N15/13

CPC分类号： C07K16/1063 ,  A61K39/42 ,  A61K45/06 ,  A61K49/0004 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1045 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  G01N33/56972 ,  G01N33/56983 ,  G01N33/56988 ,  G01N2333/161

摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

公开(公告)号：EP2705368A1

公开(公告)日：2014-03-12

申请号：EP12722545.6

申请日：2012-04-27

申请人： Apex Biosolutions ,  L'Universite De Franche Comte

发明人： HERBEIN, Georges ,  MOROT-BIZOT, Stéphanie

IPC分类号： G01N33/569

CPC分类号： G01N33/56988 ,  G01N2333/161

摘要： The invention relates to the use of at least one sub-unit of a translation elongation factor 1, EF-1, protein, of a homologue thereof, or of a C-terminal fragment of said protein and homologue, as an agent for detecting a p24 retroviral protein, or a homologue thereof.

公开(公告)号：EP2638060A2

公开(公告)日：2013-09-18

申请号：EP11784463.9

申请日：2011-11-10

申请人： LABORATORIOS DEL DR. ESTEVE, S.A. ,  Fundació Privada Institut de Recerca de la SIDA-Caixa ,  Institució Catalana de Recerca i Estudis Avançats ,  University of Washington

发明人： MOTHE PUJADAS, Beatriz ,  BRANDER, Christian ,  MULLINS, James I.

IPC分类号： C07K14/16 ,  G06F19/14 ,  G01N33/50 ,  A61K39/21 ,  A61P31/18

CPC分类号： A61K39/21 ,  A61K38/00 ,  A61K39/12 ,  A61K2039/572 ,  C07K7/08 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16021 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16222 ,  C12N2740/16234 ,  G01N33/505 ,  G01N2333/161

摘要： The invention relates to peptides comprising part or all of a conserved element within a Center-of Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides.

摘要翻译： 本发明涉及包含部分或全部保护元件的肽，所述保守元件来源于由天然存在的HIV变异体编码的多肽家族的树中（COT）序列。 本发明还涉及包含所述肽的免疫原性组合物和疫苗。 本发明还涉及基于检测患者的T细胞以鉴定针对所述肽的细胞毒性T细胞应答以及用于鉴定变体多肽家族内的免疫原性肽的方法来鉴定HIV控制患者的方法。

公开(公告)号：EP2331969A4

公开(公告)日：2012-05-16

申请号：EP09819705

申请日：2009-10-05

申请人： MOREHOUSE SCHOOL OF MEDICINE

发明人： NEWMAN GALE W ,  POWELL MIKE ,  DOHERTY AKINS ,  OBIALO CHAMBERLAIN ,  MITCHELL-ALI CLAUDETTE ,  BASHIR KHALID ,  KHAN MAFUZ

IPC分类号： G01N33/68 ,  G01N33/493 ,  G01N33/569

CPC分类号： G01N33/56988 ,  G01N1/40 ,  G01N33/493 ,  G01N33/6893 ,  G01N2333/161 ,  G01N2333/162 ,  G01N2333/163 ,  G01N2800/347 ,  G01N2800/56

公开(公告)号：EP2109772A4

公开(公告)日：2010-09-29

申请号：EP08701712

申请日：2008-01-17

申请人： NEXT BIOMED TECHNOLOGIES NBT O

发明人： SAKSELA KALLE

IPC分类号： G01N33/569 ,  C07K16/10

CPC分类号： C07K16/1054 ,  G01N33/56988 ,  G01N2333/161

公开(公告)号：EP1730135B1

公开(公告)日：2010-09-22

申请号：EP05732020.2

申请日：2005-03-09

申请人： The United States of America, represented by the Secretary, Department of Health and Human Services

发明人： DI SANTO, Roberto ,  POMMIER, Yves ,  MARCHAND, Christophe ,  ARTICO, Marino ,  COSTI, Roberta

IPC分类号： C07D401/06 ,  C07D215/56 ,  A61K31/47 ,  A61P31/18

CPC分类号： C07D403/04 ,  C07D215/233 ,  C07D215/56 ,  C07D401/06 ,  C12N9/99 ,  G01N33/56988 ,  G01N2333/161 ,  G01N2500/00

摘要： Novel quinoline inhibitors of retroviral integrase, particularly HIV-1 integrase. The quinoline inhibitors are oxoquinolines of the following formula (I) that can be used for preventing or treating AIDS or HIV infection in a subject. Wherein Z is selected from -C(O)OR2 then at least one of R3, R4, R5 or R6 is -C(O)CH2C(O)X and wherein R1, R2, R3, R5, R6 or X are as disclosed herein.